LB Pharmaceuticals Raises $100M, Holds $365.6M Cash as It Launches Two Phase Trials
LB Pharmaceuticals has initiated the pivotal Phase 3 NOVA-2 trial in acute schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression, with topline data expected in H2 2027 and Q1 2028 respectively. Following a $100 million private placement, the company holds $365.6 million in cash and marketable securities, funding operations into Q2 2029.
1. Pipeline Expansion
LB Pharmaceuticals initiated the pivotal Phase 3 NOVA-2 trial in acute schizophrenia in March 2026 and launched the 52-week NOVA-3 open-label safety trial, with topline data expected in the second half of 2027; it also began the Phase 2 ILLUMINATE-1 trial in bipolar depression, targeting first-quarter 2028 results.
2. Phase 2 Data Highlights
Results from the Phase 2 NOVA-1 trial were published in JAMA Psychiatry, demonstrating that cognitive improvements measured by the Global Cognition composite score were primarily a direct effect of LB-102 rather than an indirect consequence of symptom reduction.
3. Financing and Cash Runway
In February 2026, the company raised $100 million via private placement (net proceeds $93.8 million), boosting cash, cash equivalents and marketable securities to $365.6 million as of March 31, expected to fund operations through Q2 2029.
4. Q1 Financial Results
Research and development expenses rose to $14.6 million in Q1 2026 from $3.4 million a year earlier, driven by increased clinical trial costs, formulation production and personnel; general and administrative expenses climbed to $7.5 million from $3.0 million due to higher headcount, stock-based compensation and professional fees.